252 related articles for article (PubMed ID: 27266892)
1. Thyrotropin Receptor Antibody Levels at Diagnosis and After Thionamide Course Predict Graves' Disease Relapse.
Tun NN; Beckett G; Zammitt NN; Strachan MW; Seckl JR; Gibb FW
Thyroid; 2016 Aug; 26(8):1004-9. PubMed ID: 27266892
[TBL] [Abstract][Full Text] [Related]
2. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
[TBL] [Abstract][Full Text] [Related]
3. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease.
Schott M; Morgenthaler NG; Fritzen R; Feldkamp J; Willenberg HS; Scherbaum WA; Seissler J
Horm Metab Res; 2004 Feb; 36(2):92-6. PubMed ID: 15002058
[TBL] [Abstract][Full Text] [Related]
4. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of the 2nd generation assay for anti-TSH receptor antibodies to differentiate relapse of Graves' thyrotoxicosis from development of painless thyroiditis after antithyroid drug treatment for Graves' disease.
Izumi Y; Takeoka K; Amino N
Endocr J; 2005 Aug; 52(4):493-7. PubMed ID: 16127219
[TBL] [Abstract][Full Text] [Related]
6. Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease.
Zimmermann-Belsing T; Nygaard B; Rasmussen AK; Feldt-Rasmussen U
Eur J Endocrinol; 2002 Feb; 146(2):173-7. PubMed ID: 11834425
[TBL] [Abstract][Full Text] [Related]
7. Impact of smoking on the course of Graves' disease after withdrawal of antithyroid drugs.
Quadbeck B; Roggenbuck U; Janssen OE; Hahn S; Mann K; Hoermann R;
Exp Clin Endocrinol Diabetes; 2006 Sep; 114(8):406-11. PubMed ID: 17039420
[TBL] [Abstract][Full Text] [Related]
8. TSH receptor antibody measurements and prediction of remission in Graves' disease patients treated with minimum maintenance doses of antithyroid drugs.
Okamoto Y; Tanigawa S; Ishikawa K; Hamada N
Endocr J; 2006 Aug; 53(4):467-72. PubMed ID: 16820704
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Five TSH-Receptor Antibody Assays in Graves' disease: results from an observational pilot study.
Struja T; Jutzi R; Imahorn N; Kaeslin M; Boesiger F; Kutz A; Mundwiler E; Huber A; Kraenzlin M; Mueller B; Meier C; Bernasconi L; Schuetz P
BMC Endocr Disord; 2019 Apr; 19(1):38. PubMed ID: 31023276
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study.
Cappelli C; Gandossi E; Castellano M; Pizzocaro C; Agosti B; Delbarba A; Pirola I; De Martino E; Rosei EA
Endocr J; 2007 Dec; 54(5):713-20. PubMed ID: 17675761
[TBL] [Abstract][Full Text] [Related]
11. Clinical value of M22-based assays for TSH-receptor antibody (TRAb) in the follow-up of antithyroid drug treated Graves' disease: comparison with the second generation human TRAb assay.
Massart C; Gibassier J; d'Herbomez M
Clin Chim Acta; 2009 Sep; 407(1-2):62-6. PubMed ID: 19576193
[TBL] [Abstract][Full Text] [Related]
12. [Individual outcome monitoring of TSH receptor antibody level for predicting the prognosis of Graves' disease].
Rink T; Holle LH; Schroth HJ; Garth H
Nuklearmedizin; 1998 May; 37(3):90-4. PubMed ID: 9604228
[TBL] [Abstract][Full Text] [Related]
13. Measuring TSH receptor antibody to influence treatment choices in Graves' disease.
Hesarghatta Shyamasunder A; Abraham P
Clin Endocrinol (Oxf); 2017 May; 86(5):652-657. PubMed ID: 28295509
[TBL] [Abstract][Full Text] [Related]
14. Improved prediction of relapse of Graves' thyrotoxicosis by combined determination of TSH receptor and thyroperoxidase antibodies.
Schott M; Eckstein A; Willenberg HS; Nguyen TB; Morgenthaler NG; Scherbaum WA
Horm Metab Res; 2007 Jan; 39(1):56-61. PubMed ID: 17226115
[TBL] [Abstract][Full Text] [Related]
15. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K
J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
[TBL] [Abstract][Full Text] [Related]
16. Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment.
Wallaschofski H; Miehle K; Mayer A; Tuschy U; Hentschel B; Paschke R
Horm Metab Res; 2002 Jul; 34(7):383-8. PubMed ID: 12189586
[TBL] [Abstract][Full Text] [Related]
17. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study.
Laurberg P; Wallin G; Tallstedt L; Abraham-Nordling M; Lundell G; Tørring O
Eur J Endocrinol; 2008 Jan; 158(1):69-75. PubMed ID: 18166819
[TBL] [Abstract][Full Text] [Related]
18. [Long-term follow up after antithyroid drug treatment in Graves' disease].
Wille T; Müller B; Noth D; Bürgi U; Diem P
Praxis (Bern 1994); 2006 Jul; 95(29-30):1121-7. PubMed ID: 16916174
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes of pediatric Graves' disease.
Jevalikar G; Solis J; Zacharin M
J Pediatr Endocrinol Metab; 2014 Nov; 27(11-12):1131-6. PubMed ID: 24945422
[TBL] [Abstract][Full Text] [Related]
20. Preserved activation of thyrotropin receptor antibody to stimulate thyroid function despite long-term treatment in euthyroid patients with Graves' disease.
Akuzawa M; Murakami M; Yamada M; Satoh T; Shimizu H; Mori M
Eur J Endocrinol; 1998 Mar; 138(3):281-5. PubMed ID: 9539302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
